Bioequivalence Study of Zonisamide Capsules 100 mg of Dr.Reddy's Laboratories Limited Under Fasting Conditions
- Registration Number
- NCT01161966
- Lead Sponsor
- Dr. Reddy's Laboratories Limited
- Brief Summary
The objective of this study was to compare the rate and extent of absorption of Dr. Reddy's Zonisamide 100 mg Capsule to that of Zonegran® 100 mg Capsule after a single, one-capsule dose in fasted subjects.
- Detailed Description
This was an open label, randomized, balanced, single dose, two-period, two-treatment, two-sequence crossover study, performed under fasting conditions. Subjects were confined to the SFBC Clinical Research Facility from at least 10 hours prior to drug administration, until after the 24-hour post-dose blood draw, in each period. The treatment phases were separated by a washout period of 28 days.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 26
Inclusion Criteria
- Is the individual a healthy, normal adult man or non-child bearing potential woman who volunteers to participate?
- Is s/he at least 18 years of age?
- Is his/her BMI between 19 and 30, inclusive?
- Is s/he considered reliable and capable of understanding his/her responsibility and role in the study?
- Has s/he provided written informed consent?
Exclusion Criteria
- Does the individual have a history of allergy or hypersensitivity to zonisamide or sulfonamides?
- Does s/he have clinically significant laboratory abnormalities that would interfere with the conduct or interpretation of the study or jeopardize his/her safety? Does s/he have significant history or clinical evidence of auto-immune, cardiovascular, gastrointestinal, hematological, hematopoietic, hepatic, neurological, ongoing infection, pancreatic, or renal diseases that would interfere with the conduct or interpretation of the study or jeopardize his/her safety?
- Does s/he have serious psychological illness?
- Does s/he have significant history (within the past year) or clinical evidence of alcohol or drug abuse?
- Does s/he have a positive urine drug screen, or a positive HIV-1, or hepatitis B or C screen, or a positive pregnancy test?
- Has s/he consumed grapefruit or grapefruit juice during the 7-day period preceding study initiation?
- Is s/he unable to refrain from the use of alcohol or xanthine-containing foods or beverages during periods beginning 48 hours prior to study drug administration and ending when the last blood sample has been taken?
- Has s/he used any prescription drug during the 14-day period prior to study initiation, or any OTC drug during the 72-hour period preceding study initiation?
- Is s/he unable to refrain from the use of all concomitant medications during the study?
- Has s/he donated or lost blood, or participated in a clinical study which involved the withdrawal of a large volume of blood (480 mL or more), during the six week period preceding study initiation?
- Has s/he donated plasma during the two week period preceding study initiation?
- Has s/he received an investigational drug during the 30 day Period preceding study initiation?
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- CROSSOVER
- Arm && Interventions
Group Intervention Description Zonegran Zonegran Zonegran Capsules 100 mg of EISAI INC Zonisamide Zonisamide Zonisamide Capsules 100 mg of Dr.Reddy's laboratories Limited
- Primary Outcome Measures
Name Time Method Bioequivalence on Cmax,AUC and Tmax Parameters 3 months
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
SFBC Ft. Myers, Inc.
🇺🇸Fort Myers, Florida, United States